Literature DB >> 4066444

The influence of time sequence of cisplatin administration and continuous low dose rate irradiation (CLDRI) on their combined effects on a murine squamous cell carcinoma.

K K Fu, K N Lam, P A Rayner.   

Abstract

The influence of time sequence of cis-dichlorodiammine platinum (cisplatin) administration and continuous low dose rate irradiation (CLDRI) on their combined effects was studied in the SCC VII/SF tumor, a murine squamous cell carcinoma. Concurrent cisplatin i.p. infusion at 0.22 mg/kg/hr and CLDRI at 0.6 Gy/hr had a supraadditive effect on the survival of the SCC VII/SF tumor cells. Cisplatin by itself was more effective against the SCC VII/SF tumor when given by bolus injection than by continuous infusion i.p. However, when cisplatin at a dose of 6 mg/kg was given by bolus i.p. injection either immediately before or after CLDRI, the combined effects on the SCC VII/SF tumor cell survival were no more than additive. Exposure to CLDRI at 0.6 Gy/hr for 24 hours did not sensitize the SCC VII/SF tumor to subsequent treatment with cisplatin. These results suggest that when cisplatin is combined with CLDRI, for the optimal anti-tumor effect, it is best to infuse the cisplatin continuously during the course of CLDRI.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4066444     DOI: 10.1016/0360-3016(85)90092-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  2 in total

1.  Radioiodinated anti-hepatocellular carcinoma (HCC) ferritin. Targeting therapy, tumor imaging and anti-antibody response in HCC patients with hepatic arterial infusion.

Authors:  Z Fan; Z Tang; K Liu; D Zhou; J Lu; A Yuan; H Zhao
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001.

Authors:  Shoucheng Ning; Thillai Veerapazham Sekar; Jan Scicinski; Bryan Oronsky; Donna M Peehl; Susan J Knox; Ramasamy Paulmurugan
Journal:  Oncotarget       Date:  2015-08-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.